Bristol-Myers Squibb: A Highly Innovative Company Priced Like a Value Stock (BMY, Buy, $48.99)Friday, January 25, 2019 · 11:55 am |
|
Bristol-Myers-Squibb: Negative Market Reaction to Celgene Acquisition is a Buying Opportunity (BMY, Buy, $45.17)Thursday, January 3, 2019 · 1:26 pm |
|
Bristol-Myers Squibb: Why I Believe Its Dominance in Cancer Immunotherapy Promises to Make BMY a Great Long-Term Investment (BMY, $62.70, Buy)Monday, February 12, 2018 · 8:21 am |
|
Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)Thursday, September 7, 2017 · 9:56 am |
|
Bristol-Myers Squibb: Disappointing Recent Press Release Causes Sharp Drop in Stock Price; I Remain at Buy (BMY, Buy, $49)Tuesday, January 24, 2017 · 11:02 am |
|
Bristol-Myers Squibb: Implications of Potentially Earlier than Expected Introduction of Keytruda Combined with Chemotherapy in the First Line Lung Cancer Setting (BMY, Buy, $56.31)Thursday, January 12, 2017 · 11:52 am |
|
SmithOnStocks Top Stock Picks for 2017, January 3, 2017Tuesday, January 3, 2017 · 10:18 am |
|
Immuno-Oncology is Probably The Most Explosive Commercial Opportunity in All of BioPharma; My Investment Picks are Bristol-Myers Squibb (BMY, Buy, $57.14) and Agenus (AGEN, Buy, $4.28))Friday, December 9, 2016 · 2:37 pm |
|
Bristol-Myers Squibb: Side Effect Issue with Hepatitis C Drug Creates a Buying Opportunity (BMY, $32.55)Thursday, August 2, 2012 · 3:17 pm |
|
Bristol-Myers Squibb: Best Positioned for Growth of the Four Big US Pharma CompaniesThursday, August 2, 2012 · 5:42 am |
|
Bristol-Myers Squibb: Acquisition of Amylin is a Mild Posiitve (BMY, $35.89)Monday, July 2, 2012 · 10:53 am |
|
FDA Advisory Committee Recommendation for Approval of Xarelto Bodes Well for Approval of Eliquis (apixaban)Friday, September 9, 2011 · 9:34 am |
|
Xarelto's Problems are Eliquis' Opportunities (BMY. $29.90)Thursday, September 8, 2011 · 8:27 am |
|
New Product Potential is Outstanding But Patent Cliff is Looming (BMY, $29.28)Thursday, July 28, 2011 · 1:43 pm |
|
Eliquis Could Be A Blockbuster (BMY, $29.46)Friday, July 22, 2011 · 10:58 am |
|
Five Questions Posed by the FDA to Its Advisory Committee on Dapagliflozin (BMY, $28.96)Friday, July 15, 2011 · 2:36 pm |
|
Dapagliflozin's Date with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (BMY, $29.17)Thursday, July 14, 2011 · 9:30 am |
|
Yervoy Was A Star at American Society of Oncology: Commercial Potential Is Enormous (BMY, $29.15)Sunday, July 3, 2011 · 7:02 am |
|
Ipilimumab's March 26 PDUFA Date Is Looming (BMY, $26.00)Monday, May 9, 2011 · 3:12 pm |
|
Ipilimumab's Approved Indications Exceed Expectations (BMY, $26.93)Monday, May 9, 2011 · 2:41 pm |
|
Initiating With Buy: Weighing an Excellent New Product Outlook Against the Pending Patent Cliff (BMY, $25Monday, May 9, 2011 · 11:54 am |
|
|
There are 21 reports on file. |
